Trials of New Cancer Therapies Can’t Enroll Enough Patients
Engineering of human immune cells to fight off cancer promised to help cure the disease, and, so far, it appears to be living up to the hype. So you might think that enlisting patients to take part in trials of the new therapies would be easy. But the New York Times reports that there's a hitch. First, many biotech firms are creating similar and competing treatments. Second, they can't be offered to all patients, perhaps because their cancers are treated surgically or because they don't attend a hospital involved with research. Combined, those factors mean that many trials are failing to recruit enough people to obtain useful results—and it's even worse for targeted therapies.
Deep Dive
Uncategorized
Our best illustrations of 2022
Our artists’ thought-provoking, playful creations bring our stories to life, often saying more with an image than words ever could.
How CRISPR is making farmed animals bigger, stronger, and healthier
These gene-edited fish, pigs, and other animals could soon be on the menu.
The Download: the Saudi sci-fi megacity, and sleeping babies’ brains
10 Breakthrough Technologies 2023
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.